This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on Web of Science (5)  • Contact me when this article is cited  Related Content  • Related letters  • Similar articles in this journal  Topic Collections  • Ophthalmological Disorders, Other  • Drug Therapy  • Adverse Effects  • Alert me on articles by topic  Social Bookmarking   What's this?

Arch Ophthalmol. 2006;124:277-279.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

An important event in the treatment of inflammatory disease was the identification of selective inhibitors of cyclooxygenase-2 (COX-2). Cyclooxygenase-1 (COX-1) inhibitors are responsible for many of the adverse effects of nonsteroidal anti-inflammatory drugs, such as gastrointestinal disturbances, while blockage of COX-2 mediates the anti-inflammatory activity with fewer adverse effects. Selective COX-2 inhibitors include rofecoxib (Vioxx; Merck & Co, West Point, Pa), celecoxib (Celebrex; Pfizer Inc, New York, NY), valdecoxib (Bextra; Pfizer Inc), and lumiracoxib (Prexige; Novartis Pharmaceuticals Corp, Basel, Switzerland). Nimesulide (Ainex; Schering-Plough, Santiago, Chile) (and other trade names), and etolodac (Lodine; Wyeth, Madison, NJ) also exhibit selective COX-2 inhibition and can be included in this class of medication which is used in the treatment of osteoarthritis, rheumatoid arthritis, acute pain, and dysmenorrhea.¹ Nimesulide and lumiracoxib are not approved by the Food and Drug Administration and are not marketed in the United States and Merck removed Vioxx from the market . . . [Full Text of this Article]

Methods


Results

Conclusions

AUTHOR INFORMATION
Frederick W. Fraunfelder, MD; Jonathan Solomon, MD; Thomas J. Mehelas, MD

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED LETTERS

Adverse Effects of Cyclooxygenase-2 Inhibitors on Ocular Vision
Carsten H. Meyer, Stefan Mennel, Jörg C. Schmidt, and Peter Kroll
Arch Ophthalmol. 2006;124(9):1368.
EXTRACT | FULL TEXT  

Adverse Effects of Cyclooxygenase-2 Inhibitors on Ocular Vision—Reply
Frederick W. Fraunfelder
Arch Ophthalmol. 2006;124(9):1368.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Adverse effects of cyclooxygenase-2 inhibitors on ocular vision.
Meyer et al.
Arch Ophthalmol 2006;124:1368-1368.
FULL TEXT